These effects of BTK inhibition in antibody-mediated nephritis [15], and initial studies reporting good therapeutic results with reasonable safety in human disease (for non-lupus indications) [27], led us to the current study which was to focus the investigation on the effects of BTK inhibition in lupus-associated extra-renal involvement. This evidence concerns the gene BTK and systemic lupus erythematosus.